+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alexion Pharmaceuticals - logo

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Alexion developed Soliris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris is approved in more than 50 countries for PNH and more than 40 countries for aHUS. Alexion's company headquarters are based Cheshire, Connecticut, United States.

Licensing Deals in Biotechnology 2019-2025 - Product Thumbnail Image

Licensing Deals in Biotechnology 2019-2025

  • Report
  • April 2025
  • 1250 Pages
  • Global
From
Collaboration Deals in Biotechnology 2019-2025 - Product Thumbnail Image

Collaboration Deals in Biotechnology 2019-2025

  • Report
  • April 2025
  • 1000 Pages
  • Global
From
Biologics Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Biologics Market - Forecasts from 2024 to 2029

  • Report
  • April 2024
  • 121 Pages
  • Global
From
From
From
Rare Diseases Market Report 2024-2034 - Product Thumbnail Image

Rare Diseases Market Report 2024-2034

  • Report
  • May 2024
  • 344 Pages
  • Global
From
Autoimmune Treatment Market Report 2025 - Product Thumbnail Image

Autoimmune Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Systemic Lupus Erythematosus - Pipeline Review, H2 2020 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 816 Pages
  • Global
From
Myositis - Pipeline Insight, 2024 - Product Thumbnail Image

Myositis - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 80 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market Report 2025 - Product Thumbnail Image

Transthyretin Amyloidosis Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
From
Mucopolysaccharidosis III - Pipeline Insight, 2024 - Product Thumbnail Image

Mucopolysaccharidosis III - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Complement C5 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement C5 inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator